---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-100929"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2026-09-17T19:37:59+00:00"
generated_at: "2026-09-17T19:39:13.629512+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# ORMP shareholders re-elect board, approve incentive plan increase and triennial say-on-pay

## Summary
- All six directors re-elected; favorable votes ranged from 11.57M (Shapiro) to 13.70M (N. Kidron).
- Ratification of Kesselman & Kesselman (PwC member) as 2026 fiscal year auditor passed: 22.24M for, 2.72M against.
- 2019 Stock Incentive Plan amendment approved, increasing authorized shares by 3M to 12.5M total.
- Say-on-pay approved (13.01M for, 4.39M against); stockholders selected every-three-years frequency (11.38M for).
- Board adopted triennial say-on-pay votes until the next required frequency vote.

## SEC filing metadata
- accession: 0001213900-26-100929
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2026-09-17T19:37:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390026100929/0001213900-26-100929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390026100929/ea0305871-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-100929
- JSON: https://secwatch.observer/filing/0001213900-26-100929.json
- Plain text: https://secwatch.observer/filing/0001213900-26-100929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.